ADCT
ADC Therapeutics S.A.
There isn't enough reported data to score ADCT yet.
ADCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ADCT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
ADCT PE Valuation
ADCT has no meaningful PE right now: it lost money over the past year.
ADCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ADCT's losses to shrink, with revenue growing.
ADCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.53 | +$0.89 |
| Q2 2026 | -$0.67 | +$0.87 |
| Q1 2026 | -$1.06 | +$0.36 |
| Q4 2025 | -$1.21 | +$0.41 |
| Q3 2025 | -$1.42 | +$0.97 |
| Q2 2025 | -$1.54 | +$1.01 |
| Q1 2025 | -$1.42 | +$1.33 |
| Q4 2024 | -$1.62 | +$1.30 |
ADCT is still losing money, but far less than before: $0.53 per share over the past year, against $3.71 at its worst in late 2020.
ADCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.7M | +32% |
| Q2 2026 | $19.2M | +2.2% |
| Q1 2026 | $20.9M | -9.5% |
| Q4 2025 | $23.1M | +36% |
| Q3 2025 | $16.4M | -11% |
| Q2 2025 | $18.8M | +8.2% |
| Q1 2025 | $23M | +28% |
| Q4 2024 | $16.9M | +0.7% |
ADCT's revenue is recovering but still below its 2022 peak: $22M last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -66% | +122 points |
| Q2 2026 | -132% | +102 points |
| Q1 2026 | -121% | +2.5 points |
| Q4 2025 | -78% | +114 points |
| Q3 2025 | -189% | +4.1 points |
| Q2 2025 | -234% | -68 points |
| Q1 2025 | -124% | +63 points |
| Q4 2024 | -192% | +46 points |
ADCT's operating margin was −66% last quarter, up 122 points from the same quarter a year ago.
ADCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.9M | +$1.8M |
| Q2 2026 | -$11.8M | +$12.3M |
| Q1 2026 | -$29.7M | +$26.9M |
| Q4 2025 | -$31.1M | -$9.2M |
| Q3 2025 | -$29.6M | -$4.4M |
| Q2 2025 | -$24.1M | +$8.8M |
| Q1 2025 | -$56.6M | -$12M |
| Q4 2024 | -$21.9M | +$11.1M |
ADCT has burned cash in almost every quarter: −$101M over the past year, against −$132M the year before.
ADCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +394K shares |
| 1 year | +14% | +19M shares |
| 3 years | +89% | +73.2M shares |
| 5 years | +103% | +78.7M shares |
| Available history | +112% | +82.2M shares |
ADCT has 155M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $218,871 |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
ADCT Net Leverage
ADCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ADCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 61.0 | Neutral |
ADCT's weekly RSI is 44 (neutral) and its Stochastic is 61 (neutral).
ADCT PE vs Healthcare Sector
ADCT has no meaningful PE right now: it lost money over the past year.
ADCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 2.1% below |
| 20 week MA | $1.26 | 12% above |
| 50 week MA | $2.55 | 45% below |
| 100 week MA | $2.60 | 46% below |
| 200 week MA | $2.64 | 47% below |
ADCT's trend is mixed: it's above one of its five weekly moving averages, and 47% below its 200-week average.
ADCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $37.0 | +25% |
| 2021 | $37.0 | $21.3 | -43% |
| 2022 | $21.3 | $3.52 | -83% |
| 2023 | $3.52 | $1.66 | -53% |
| 2024 | $1.66 | $2.03 | +22% |
| 2025 | $2.03 | $3.51 | +73% |
| 2026 YTD | $3.51 | $1.41 | -60% |
ADCT has finished lower in three of the last six years. It's down 60% so far in 2026.